{
  "meta": {
    "timestamp": "2025-01-06T14:17:02.223387",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Tyra Biosciences Inc.",
      "symbol": "TYRA",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "High uncertainty in early-stage clinical trials, with potential failure to demonstrate efficacy or safety",
            "Intense competition in the FGFR inhibitor space from established players like Incyte and QED Therapeutics",
            "Regulatory hurdles, including potential delays in FDA approvals or unexpected requirements",
            "Significant funding challenges, with reliance on external capital and concerns about future dilution or debt financing",
            "Increased short interest, reflecting growing skepticism among some investors"
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "Addressing unmet medical needs in oncology, particularly for patients with resistant cancers"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Tyra Biosciences, Inc | European Clinical Trials Information Network",
              "snippet": "Tyra Biosciences, Inc is a biotechnology company that specializes in developing innovative therapies for cancer treatmen. Menu. Search for Clinical Trials. Autoimmunity. Cancers. Cardiovascular and Blood Diseases. CNS Disorders. Endocrine Diseases. Genetic Diseases. Liver Diseases. Metabolic Diseases. Liver Diseases. Respiratory System Diseases.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778179+00:00",
              "published_date": null,
              "source_hash": "42ddbf8c797277e4dca2b0b7b795d10c"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for ...",
              "snippet": "Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778289+00:00",
              "published_date": null,
              "source_hash": "1884a5bba2e47e88d0c6941b42a36d85"
            },
            {
              "url": "",
              "title": "Tyra Biosciences | Next-Generation Precision Medicines",
              "snippet": "Developing Next-Generation Precision Molecules TAKE A CLOSER LOOK. Contact; Terms & Conditions; Privacy Policy",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853205+00:00",
              "published_date": null,
              "source_hash": "8b50d286454cc68b5e4b50e06e987e5c"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase ...",
              "snippet": "CARLSBAD, Calif., Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878275+00:00",
              "published_date": null,
              "source_hash": "61e1fe23ae7d684ab55ba8a30731e809"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. - Drug pipelines, Patents, Clinical trials - Synapse",
              "snippet": "Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company's first presentation of human data since its inception in 2018.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778323+00:00",
              "published_date": null,
              "source_hash": "082d47aa374af7a391f2233fbfbdbd6c"
            },
            {
              "url": "",
              "title": "Tyra Biosciences' Q3 2024: Clinical Progress and Financial ... - TipRanks",
              "snippet": "Key financial metrics from the report included a net loss of $24.0 million for the third quarter, with research and development expenses rising to $22.7 million due to ongoing clinical trials and related costs. Tyra Biosciences ended the quarter with $360.1 million in cash, which they project will fund operations through 2026.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778332+00:00",
              "published_date": null,
              "source_hash": "4b37dd513a84a661d6aa3aaf53b8f3c1"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase ...",
              "snippet": "Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878478+00:00",
              "published_date": null,
              "source_hash": "2b6ee160d37c3f0915e68d6597f2f5dc"
            },
            {
              "url": "",
              "title": "Tyra Biosciences (TYRA) Stock Price, News & Analysis - MarketBeat",
              "snippet": "Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. ... Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778350+00:00",
              "published_date": null,
              "source_hash": "5fbbf0f4c1fcec1522fd51f448dca367"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (TYRA) - Yahoo Finance",
              "snippet": "Find the latest Tyra Biosciences, Inc. (TYRA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... which is in Phase 1/2 clinical trials ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778359+00:00",
              "published_date": null,
              "source_hash": "7b7109a21972e9ec50ee4f527ba5757e"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (TYRA) Company Profile & Overview - Stock Analysis",
              "snippet": "Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. ... TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:34.778368+00:00",
              "published_date": null,
              "source_hash": "53b05a5ed9f4589cbb7ca8639bfbd6a1"
            },
            {
              "url": "",
              "title": "Tyra Bioscience, Inc",
              "snippet": "Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:47.269523+00:00",
              "published_date": "2023-04-27T16:27:00+00:00",
              "source_hash": "ad4f20e333376e8ad7c21b9d6eb3185b"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (NASDAQ:TYRA) Position Raised by Charles Schwab Investment Management Inc.",
              "snippet": "Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SN\u00c5P ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:37.290914+00:00",
              "published_date": "2024-12-14T00:00:00+00:00",
              "source_hash": "40b5a6e35877849556c0856cbb572751"
            },
            {
              "url": "",
              "title": "The Take On Tyra Biosciences",
              "snippet": "Tyra Biosciences, Inc. is a Carlsbad, California based clinical-stage biopharmaceutical ... in a dose-finding and proof-of-concept Phase 1/2 trial (SURF301) for heavily pre-treated patients ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:37.290933+00:00",
              "published_date": "2024-12-18T00:16:00+00:00",
              "source_hash": "d4ba796b79a89dbe9182351af7eb98be"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights",
              "snippet": "CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:41.353502+00:00",
              "published_date": "2024-11-07T21:05:00+00:00",
              "source_hash": "3c8564b0642f1f1cb9d89102ec1cf68a"
            },
            {
              "url": "",
              "title": "Analyzing Checkpoint Therapeutics (NASDAQ:CKPT) & Tyra Biosciences (NASDAQ:TYRA)",
              "snippet": "The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to ... Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Tyra Biosciences, Inc., a ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:37.290953+00:00",
              "published_date": "2024-12-28T23:59:00+00:00",
              "source_hash": "8247728c8c5d81262a7e44f0497436d9"
            },
            {
              "url": "",
              "title": "Release Details - Tyra Biosciences, Inc.",
              "snippet": "About Tyra Biosciences. Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SN\u00c5P, enables rapid and precise drug design through iterative molecular SN\u00c5Pshots ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878378+00:00",
              "published_date": null,
              "source_hash": "85dc5f0a8ea5f2f7db7dadb950393499"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Pipeline & Targets",
              "snippet": "TYRA-200 is being evaluated in a multi-center, open label Phase 1 clinical study, SURF201 (Study in PrevioUsly treated and Resistant FGFR2+ Cholangiocarcinoma and Other Advanced Solid Tumors). SURF201 (NCT06160752) was designed to determine the MTD and the RP2D of TYRA-200, as well as to evaluate the preliminary antitumor activity of TYRA-200.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878402+00:00",
              "published_date": null,
              "source_hash": "24d4881cb2ed5a45919ac963d8817513"
            },
            {
              "url": "",
              "title": "BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data ...",
              "snippet": "BofA has upgraded Tyra Biosciences from Neutral to Buy with a price target of $31, up from $22, ahead of the upcoming presentation of the phase 1/2 SURF-301 of TYRA-300 for urothelial carcinoma ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853287+00:00",
              "published_date": null,
              "source_hash": "05f7f5ae362e4f03f495745a00dddf0c"
            },
            {
              "url": "",
              "title": "Tyra Biosciences granted IND clearance from FDA for Phase 2 study of ...",
              "snippet": "Tyra Biosciences announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed with a Phase 2 clinical trial of Tyra-300 for children with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878424+00:00",
              "published_date": null,
              "source_hash": "26759dd151b8fe528e52af6d31f6ab26"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for ...",
              "snippet": "CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today clinical proof-of-concept data for TYRA-300 in patients with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878433+00:00",
              "published_date": null,
              "source_hash": "f673a8519d3d913697a219bafba8c300"
            },
            {
              "url": "",
              "title": "FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com",
              "snippet": "Tyra Biosciences has also reported positive results from its SURF-301 Phase 1/2 trial of TYRA-300 in metastatic urothelial carcinoma, leading to H.C. Wainwright raising the price target to $32.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878443+00:00",
              "published_date": null,
              "source_hash": "709a9535ea512f5746e27283300cf90a"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Doses First Patient with TYRA-200 and Provides ...",
              "snippet": "Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878460+00:00",
              "published_date": null,
              "source_hash": "d3426a69686ac0d0b36cecc640132ba5"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase ...",
              "snippet": "Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:38.878469+00:00",
              "published_date": null,
              "source_hash": "871f841dda784295fff027985fe4daa6"
            },
            {
              "url": "",
              "title": "The Take On Tyra Biosciences",
              "snippet": "Tyra Biosciences, Inc. is a Carlsbad, California based clinical-stage biopharmaceutical concern focused on the development of precision medicines that leverage its expertise in fibroblast growth ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:47.269556+00:00",
              "published_date": "2024-12-18T00:16:00+00:00",
              "source_hash": "4a80718d20356e64cf45aca1537fc875"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (NASDAQ:TYRA) Position Raised by Charles Schwab Investment Management Inc.",
              "snippet": "Charles Schwab Investment Management Inc. lifted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 2.2% during the third quarter, Holdings Channel.com reports.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:41.353488+00:00",
              "published_date": "2024-12-14T00:00:00+00:00",
              "source_hash": "fd77dfa4d01422c93b6c8c8c6a4fddc0"
            },
            {
              "url": "",
              "title": "TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023",
              "snippet": "Tyra Biosciences (NASDAQ:TYRA) just reported results for the fourth quarter of 2023. Tyra Biosciences reported earnings per share of -53 cents. This was below the analyst estimate for EPS of -48 ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:41.353511+00:00",
              "published_date": "2024-03-20T02:05:00+00:00",
              "source_hash": "ecde4f6fcc20d7649c58e4ab81642755"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer",
              "snippet": "Tyra Biosciences, Inc ... regulatory authorities for the conduct of clinical trials of TYRA-300 in pediatric achondroplasia and hypochondroplasia; an accelerated development or approval pathway ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:41.353521+00:00",
              "published_date": "2024-11-12T00:00:00+00:00",
              "source_hash": "7bc4cbd64e3d7e0ebf365055db2d1763"
            },
            {
              "url": "",
              "title": "Tyra Bio Investor Relations - Overview",
              "snippet": "Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SN\u00c5P, enables the rapid and precise refinement of structural drug design through iterative molecular ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853082+00:00",
              "published_date": null,
              "source_hash": "9852a98655a3e03d3fe7db7ec0cc381f"
            },
            {
              "url": "",
              "title": "Tyra Biosciences (TYRA) Stock Price, News & Analysis - MarketBeat",
              "snippet": "Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. ... Short interest in Tyra Biosciences has recently increased by 25.87%, indicating that investor sentiment is decreasing significantly. Dividend 0.0 / 5 Dividend Strength N/A ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853221+00:00",
              "published_date": null,
              "source_hash": "9e7bbf1dfaf8146f34cb6df643c36181"
            },
            {
              "url": "",
              "title": "Tyra Bio Investor Relations - News Releases",
              "snippet": "Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853233+00:00",
              "published_date": null,
              "source_hash": "2aef02f2767951a1d0af6e4941404c90"
            },
            {
              "url": "",
              "title": "FAQs - Tyra Bio Investor Relations",
              "snippet": "How can I view documents Tyra Biosciences has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q? Quarterly & Annual reports and other investor materials are available in the \"Investors\" section of Tyra Biosciences' corporate website.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853244+00:00",
              "published_date": null,
              "source_hash": "a86c2bc422e32b1965fc01c5e1207c19"
            },
            {
              "url": "",
              "title": "Bank of America Securities Sticks to Their Buy Rating for Tyra ...",
              "snippet": "Tyra Bioscience (TYRA) Company Description: Tyra Biosciences Inc is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853255+00:00",
              "published_date": null,
              "source_hash": "29f9a08577751df5d6596799bae2c97d"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (TYRA) Stock Price, Quote & News - Stock Analysis",
              "snippet": "Get a real-time Tyra Biosciences, Inc. (TYRA) stock price quote with breaking news, financials, statistics, charts and more. ... Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm. LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853266+00:00",
              "published_date": null,
              "source_hash": "e7f049d7dfbdae1afda71fb597b40686"
            },
            {
              "url": "",
              "title": "Tyra Biosciences ( TYRA ) - Investor's Business Daily",
              "snippet": "Stocks To Watch: Tyra Biosciences Inc Sees Relative Strength Rating Rise To 86. Investor's Business Daily 11/05/2021 03:00 AM ET. IBD Partners. No News Available. STOCK/COMPANY DATA FOR TYRA . Stock Data. Today's Range; 14.06 - 14.53; 52-Week Range; 11.24 - 29.60 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853276+00:00",
              "published_date": null,
              "source_hash": "9c661f4052884a4ff2e102f15954b8dc"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (TYRA) Company Profile & Overview - Stock Analysis",
              "snippet": "Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SN\u00c5P, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:44.853297+00:00",
              "published_date": null,
              "source_hash": "4181154e7e952a8e117b06295c09e5e9"
            },
            {
              "url": "",
              "title": "Bank of America Securities Sticks to Their Buy Rating for Tyra Bioscience (TYRA)",
              "snippet": "In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Tyra Bioscience (TYRA - Research Report),",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:47.269442+00:00",
              "published_date": "2025-01-06T11:38:00+00:00",
              "source_hash": "5b2033e9d789f274800e956b56891427"
            },
            {
              "url": "",
              "title": "Tyra Biosciences Inc",
              "snippet": "We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:47.269536+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "a527559c90184671df66de2a1ab7f799"
            },
            {
              "url": "",
              "title": "Tyra Biosciences, Inc. (NASDAQ:TYRA) Position Raised by Charles Schwab Investment Management Inc.",
              "snippet": "Charles Schwab Investment Management Inc. lifted ... investors have also modified their holdings of TYRA. Perceptive Advisors LLC raised its stake in shares of Tyra Biosciences by 50.5% during ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tyra Biosciences Inc. Tyra Biosciences Inc. investor disputes",
              "retrieved_at": "2025-01-06T21:16:47.269546+00:00",
              "published_date": "2024-12-14T00:00:00+00:00",
              "source_hash": "c051465a3da85e5c6af89b559524b00e"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Tyra Biosciences Inc. clinical trial failures",
              "rationale": "Investigate risks related to the success of clinical trials and potential legal implications",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Tyra Biosciences Inc. regulatory approval delays",
              "rationale": "Examine potential delays or issues with FDA approvals impacting pipeline progress",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Tyra Biosciences Inc. investor disputes",
              "rationale": "Assess any controversies or disputes with investors regarding funding or financial health",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:17:02.223395",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}